Works by Nakahama, Kenji


Results: 13
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12

    Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 6, p. 1598, doi. 10.1007/s10637-021-01147-w
    By:
    • Kaneda, Hiroyasu;
    • Sawa, Kenji;
    • Daga, Haruko;
    • Okada, Asuka;
    • Nakatani, Yuki;
    • Atagi, Shinji;
    • Okishio, Kyoichi;
    • Tani, Yoko;
    • Matsumoto, Yoshiya;
    • Ogawa, Koichi;
    • Nakahama, Kenji;
    • Izumi, Motohiro;
    • Mitsuoka, Shigeki;
    • Kawaguchi, Tomoya
    Publication type:
    Article
    13

    Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer.

    Published in:
    Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-70214-y
    By:
    • Sugimoto, Akira;
    • Kaneda, Hiroyasu;
    • Yoshimoto, Naoki;
    • Nagata, Kenji;
    • Fujii, Tatsuo;
    • Michimoto, Koichi;
    • Ueno, Shunsuke;
    • Kamimori, Takao;
    • Ishii, Yoshie;
    • Sakagami, Mai;
    • Inokuchi, Haruo;
    • Shibuya, Keiko;
    • Mizutani, Megumi;
    • Nagamine, Hiroaki;
    • Nakahama, Kenji;
    • Matsumoto, Yoshiya;
    • Tani, Yoko;
    • Sawa, Kenji;
    • Kawaguchi, Tomoya
    Publication type:
    Article